In the year 1998, Clay Siegall established Seattle Genetics which to date is a leader in the biotech industry. For the time over, he has shared blogs regarding various issues on his WordPress page. Most of the issues are aimed at bringing awareness to people. One of them is relating to the End of Life Option Act that is active in California. The Californians have the provision to receive the life-ending prescription. John Minor is one of the people who took the medication and is said to have had a peaceful death.
Another post is one advocating for people to appreciate clean water wherever they are.
Besides sharing blogs that are life-changing and educational, Clay Siegall has through his foundation improved the treatment of cancer patients. His company does research and development of innovative drugs for cancer. He is of great influence to the rising of the enterprise. The FDA gave Seattle Genetics the green light to go ahead and develop the antibody conjugates. The company has subsequently developed 20 more drugs and at the same time continued to improve its working relations with manufacturers that are well reputed such as Genentech, Pfizer, and Bayer. Clay Siegall has ensured that the standards of the company are not as they were in a few years past. He has overseen the company’s transition which kicked off with a few researchers to the current home of cancer research and drug development domain.
The world of medicine and modern technologies were areas that intrigued Clay Siegall. He always had the burden of putting his innovation to practice and as such offer the appropriate solution to the affected people. He had an undying urge for replacing the crude options for treatment and providing the best treatment methods as well as enjoy the outcomes of his patents. The success the firm is attributed to Clay Siegall’s desire to win in the cancer research. His interest in cancer research cropped up while he still was at the University of Maryland studying Zoology. He later got his doctorate from George Washington University. He was then hired as a junior research scientist at the National Cancer Institute.